^
Association details:
Biomarker:KIAA1549-BRAF fusion
Cancer:Glioma
Drug:Mekinist (trametinib) (MEK inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.

Excerpt:
...- Group 3: Progressing/Refractory LGG with KIAA1549-BRAF fusion (42 patients)....
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Response to trametinib treatment in progressive pediatric low-grade glioma patients

Published date:
10/07/2020
Excerpt:
In this multi-center retrospective centrally reviewed study, we analyzed 18 patients treated with the MEKi trametinib for progressive pLGG...Alterations detected included 8 KIAA1549:BRAF-fusions, three NF1 alterations, one BRAF V600E mutation and one FGFR1 K654Q mutation....We observed 6 partial responses (PR), 2 minor responses (MR), and 10 stable diseases (SD) as best overall responses....Responses were observed in KIAA1549:BRAF- as well as neurofibromatosis type 1 (NF1)-driven tumors. Median treatment time was 12.5 months (range: 2 to 27 months)....
DOI:
10.1007/s11060-020-03640-3